To be advised

Main information

  • Trade name:
  • To be advised - Disinfectant, hospital grade
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • To be advised - Disinfectant, hospital grade
    Australia
  • Language:
  • English

Other information

Status

  • Source:
  • Dept. of Health,Therapeutic Goods Administration - Australia
  • Authorization number:
  • 218203
  • Last update:
  • 08-10-2017

Public Assessment Report

Public Summary

Summary for ARTG Entry:

218203

Novapharm Research (Australia) Pty Ltd, Asepti Active 24/7, Hospital grade disinfectant without claims,

non-sterile

ARTG entry for

Other Therapeutic Good - Listed disinfectant

Sponsor

Novapharm Research (Australia) Pty Ltd

Postal Address

PO Box 151,ROSEBERY NSW, NSW, 2018

Australia

ARTG Start Date

6/12/2013

Product category

Other Therapeutic Good

Status

Active

Approval area

Medical Devices

Conditions

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods

Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered

or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Products

1. To be advised - Disinfectant, hospital grade

Product Type

Single Device Product

Effective date

6/12/2013

GMDN

9950 Disinfectant, hospital grade

Intended purpose

Hospital Grade Disinfectant Detergent for Single Step Cleaning and Disinfection

Provides up to 7 days Residual Biocidal Efficacy.

Asepti Active 24/7 provides a tack free residual sanitising film which is suitable for use on high traffic

areas. The residual film provides broad spectrum bactericidal efficacy against vegetative bacteria including

VRE, MRSA and Clostridium difficile. The residual film produced by Asepti Active 24/7 provides greater

than 3 log reduction in vegetative bacteria within 10-15 min.

The residual film of Asepti 24/7 provides residual efficacy up to 24 hours in high traffic areas and up to 7

days for low traffic areas.

Specific Conditions

No Specific Conditions included on Record

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Public Summary

Page 1 of

Produced at 10.11.2017 at 11:26:35 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information

28-9-2018

EpiPen and EpiPen Jr auto-injectors may stick in their carrier tube

EpiPen and EpiPen Jr auto-injectors may stick in their carrier tube

Pfizer Canada has advised Health Canada that, in a very small number of cases, some EpiPen (0.3 mg) and EpiPen Jr (0.15 mg) auto-injector devices may not slide out of their carrier tube easily, or at all. This could delay or prevent emergency treatment, possibly leading to patient disability or death.

Health Canada

5-7-2018

Recall of valsartan blood pressure medicine

Recall of valsartan blood pressure medicine

Impurities that could potentially be harmful to health have been found in variants of medicines containing the active substance valsartan. The medicine is used to treat hypertension and heart failure. Patients treated with these medicines are therefore advised to contact their doctor as soon as possible to be switched to another type of medicine.

Danish Medicines Agency

There are no news related to this product.